Ramucirumab
Approved medicineAlso known as Cyramza.
Recent clinical, regulatory, research and industry developments relating to this drug.
Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes2
Journals, researchers & institutions
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology1
- Journal of experimental & clinical cancer research : CR1
- Journal of the National Comprehensive Cancer Network : JNCCN1
- Ajani JA1
- Al Baghdadi T1
- Bentrem DJ1
- Chao J1
- Corvera C1
- D'Amico TA1
- Das P1
- Denlinger CS1
- Abramson Cancer Center at the University of Pennsylvania.1
- Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute.1
- Cedars-Sinai Medical Center1
- City of Hope National Medical Center.1
- Dana-Farber/Brigham and Women's Cancer Center.1
- Dartmouth-Hitchcock Norris Cotton Cancer Center1
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 5 of the same disease areas as Ramucirumab in the shared literature.
Studied across 4 of the same disease areas as Ramucirumab in the shared literature.
Studied across 3 of the same disease areas as Ramucirumab in the shared literature.
Studied across 2 of the same disease areas as Ramucirumab in the shared literature.
Studied across 2 of the same disease areas as Ramucirumab in the shared literature.
Studied across 2 of the same disease areas as Ramucirumab in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- Europe PMC — research literature